Technical Analysis for IPA - ImmunoPrecise Antibodies Ltd.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Signal Line Cross | Bearish | -8.03% | |
New 52 Week Closing Low | Bearish | -8.03% | |
Wide Bands | Range Expansion | -8.03% | |
Down 3 Days in a Row | Weakness | -8.03% | |
Down 4 Days in a Row | Weakness | -8.03% | |
Down 5 Days in a Row | Weakness | -8.03% | |
Hammer Candlestick | Bullish | -13.01% | |
Narrow Range Bar | Range Contraction | -13.01% | |
Wide Bands | Range Expansion | -13.01% | |
Down 3 Days in a Row | Weakness | -13.01% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 1 hour ago |
Outside Day | about 1 hour ago |
Down 5% | about 1 hour ago |
Down 3% | about 1 hour ago |
Up 5% | about 1 hour ago |
Free Daily (Stock) Chart Reading
- Earnings date: 12/12/2024
ImmunoPrecise Antibodies Ltd. Description
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Immunology Antibodies Monoclonal Antibody Antibody Cloning Screening
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.6 |
52 Week Low | 0.3503 |
Average Volume | 636,470 |
200-Day Moving Average | 1.04 |
50-Day Moving Average | 0.55 |
20-Day Moving Average | 0.47 |
10-Day Moving Average | 0.44 |
Average True Range | 0.06 |
RSI (14) | 34.21 |
ADX | 19.08 |
+DI | 16.30 |
-DI | 22.52 |
Chandelier Exit (Long, 3 ATRs) | 0.50 |
Chandelier Exit (Short, 3 ATRs) | 0.54 |
Upper Bollinger Bands | 0.61 |
Lower Bollinger Band | 0.33 |
Percent B (%b) | 0.21 |
BandWidth | 60.57 |
MACD Line | -0.04 |
MACD Signal Line | -0.04 |
MACD Histogram | -0.0006 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.45 | ||||
Resistance 3 (R3) | 0.45 | 0.43 | 0.44 | ||
Resistance 2 (R2) | 0.43 | 0.41 | 0.43 | 0.43 | |
Resistance 1 (R1) | 0.41 | 0.40 | 0.40 | 0.41 | 0.43 |
Pivot Point | 0.39 | 0.39 | 0.38 | 0.39 | 0.39 |
Support 1 (S1) | 0.37 | 0.37 | 0.36 | 0.36 | 0.34 |
Support 2 (S2) | 0.34 | 0.36 | 0.34 | 0.34 | |
Support 3 (S3) | 0.32 | 0.34 | 0.33 | ||
Support 4 (S4) | 0.32 |